Preliminary data from Annovis Bio’s Phase II study of ANVS401 shows significant cognitive improvements in Alzheimer’s patients after only one month of treatment.

Preliminary data from a study conducted at the University of Oxford indicates that the Covid-19 vaccine developed by AstraZeneca is effective against the Brazilian variant P1, a source with knowledge of the study told Reuters on March 5.

U.S. and European regulators could approve Pfizer and BioNTech’s experimental Covid-19 vaccine as early as mid-December, the German firm’s chief executive said, following the release of positive trial results.